CONCISE REVIEW

POPULATION SCREENING FOR LIVER FIBROSIS: TOWARDS EARLY DIAGNOSIS AND INTERVENTION FOR CHRONIC LIVER DISEASES

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/HEP.32163

This article is protected by copyright. All rights reserved
Abstract word count: 210

Manuscript word count: 3,407

Affiliations

1Liver Unit Hospital Clinic,
2İnstitut D'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS),
3Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas (Ciberehd), Barcelona, Spain;
4Dept of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, Spain.
5Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France
6Université de Paris, Paris, France
7Inserm UMR 1149, Centre de Recherche Sur L'inflammation, Paris, France.
8Department of Medicine II, Saarland University Medical Center, Homburg, Germany.
9Institute for Occupational Medicine and Public Health, Saarland University, Homburg, Germany
10Health Sciences, Hannover Medical School MHH, Hannover, Germany
11Epidemiology, Statistics, and Prevention Institute, University of Zurich, Switzerland
12Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA
13The Chinese University of Hong Kong, Dept. of Medicine and Therapeutics, Hong Kong
14Division of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, University of
California San Diego, La Jolla, USA
15 Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, and Institute for Clinical Research, University of Southern Denmark Odense, Denmark
16 USR Metropolitana Nord, IDIAP Jordi Gol, ICS Institut Català de la Salut, Spain.
17 Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands
18 Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia
19 Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Spain.
20 Universitat Autònoma de Barcelona, Barcelona, Spain.
21 UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College of London (UCL), London, UK.
22 Metabolic Liver Research Program, Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany.
23 NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
24 Unit of Internal Medicine and Hepatology (UIMH), Dept. of Medicine (DIMED), University-Teaching Hospital of Padova, Italy
25 Liver Unit, Hospital Germans Trias i Pujol, IGTP, Badalona, Spain
26 Liver Section, Gastroenterology Department, Hospital del Mar, Departament of Medicine, IMIM, Barcelona, Spain
27 Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands
28 School of Nursing, Faculty of Medicine and Health Sciences, University of Barcelona, Spain.
29 Clinical Trial Unit, Hospital Clinic, 08036 Barcelona, Spain.
30 Department of Pathology. Centre of Biomedical Diagnosis. Hospital Clinic. Barcelona, Spain
31 Unité d’Hépatologie, Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny, France
32 European Association for the Study of the Liver (EASL), Geneva Switzerland.
33 National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, UK.
* Supported by the LiverScreen Consortium and funded by the European Commission under the program H20/20 to investigate screening for liver fibrosis and its applicability in European countries (www.liverscreen.eu)

Keywords: Cirrhosis, Screening, fibrosis, chronic liver diseases, NAFLD, NASH

GRANT FUNDING
The work described has been funded by a EC_H2020 SC1 Grant LIVERSCREEN-Project number: 847989. PG and members of his group have been supported by AGAUR 2017SGR-01281. CIBER (Centro de Investigacion Biomedica en Enfermedades Hepaticas y Digestivas). PI18/01330- PI18/00662 – PI18/00862 from the Fundación de Investigación sanitaria and cofunded by Instituto Carlos III (ISCIII)-Subdirección General de Evaluación and the European Regional Development Fund.
Also supported in part by a grant from Gilead’s Investigator sponsored research program: study number IN-ES-989-5309.

Declaration of Conflict of Interest

PG declares he has received Investigator Initiated Research funding from: Gilead, Grifols and Mallinckrodt Pharmaceuticals: He has participated on advisory boards or consultancy for: Gilead, Grifols, Mallinckrodt, Novartis, Martin Pharmaceuticals, and Ferring.


IG: Speaking fees from Gilead, Abbvie, Intercept.

VWSW: has served as a consultant or advisory board member for 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Merck, Novartis, Novo Nordisk, Perspectum
Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, and Terns; and a speaker for AbbVie, Bristol-Myers Squibb, Echosens, and Gilead Sciences. He has also received a research grant from Gilead Sciences for fatty liver research.

MT: Speaking fees from Siemens, Echosens, Norgine; consultancy fee from GE Healthcare.

RJK: has received Investigator Initiated Research funding from: Gilead, has worked on advisory boards for: AbbVie, BMS, Gilead, Merck, has spoken for AbbVie, Echosens, Gilead, Philips.

SA reports having received consulting fees from Boehringer Ingelheim, Gilead, Intercept, Novartis, Pfizer, Ferrer, IQVIA. He has received speaking fees from Allergan, Gilead, MSD and Novartis and travel expenses from Gilead, MSD, Novo Nordisk, Janssen, Genfit, Bayer and Ferring. He has received research support from Gilead and MRM Health

EAT: Consulting fees from Gilead, Intercept, Pfizer and Orphalan.

JMS: Consultancy: Boehringer Ingelheim, BMS, Echosens, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Novartis, Novo Nordisk, Nordic Bioscience, Pfizer, Roche, Sanofi, Siemens Healthcare GmbH. Research Funding: Gilead Sciences, Boehringer Ingelheim, Siemens Healthcare GmbH. Speakers Bureau: Falk Foundation MSD Sharp & Dohme GmbH

RMM: Speaker: Gilead, Abbvie, Intercept ; Consultant: Intercept, AbbVie

HJdK reports speakers’ fee from MSD on lung cancer screening symposium

AK has served as speaker for Norgine, Siemens and Nordic Bioscience and participated in advisory boards for Norgine and Siemens, all outside the submitted work.

All other authors have declared no conflicts.
SUMMARY

Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy non-invasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using non-invasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate –18 to 27%- in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.
Cirrhosis is the 11th commonest cause of death globally accounting for an estimated 2 million deaths per year (1) with data from the Global Burden of Disease Study indicating cirrhosis deaths have risen from 899 000 to more than 1.32 million from 1990 to 2017 (2). Moreover, there is marked geographical variation with Central Asia having the highest age-standardized death rate (39 deaths [36.2-41.5 95% CI] per 100,000 population) in contrast to the lowest rates seen in Australasia (5.4 [4.9-6.0 95% CI] per 100,000 population) (2).

Approximately 75 million individuals worldwide have an alcohol-use disorder putting them at risk for alcohol-related liver disease (ALD). With over 2 billion adults being obese/overweight and over 400 million with diabetes, the increase in age-standardized prevalence of compensated and decompensated cirrhosis has been higher with non-alcoholic fatty liver disease (NAFLD) as compared with other etiologies of liver disease (increase of 33% for compensated cirrhosis and 55% for decompensated cirrhosis, with NAFLD as compared to other etiologies of cirrhosis) (2). The recognized interaction between obesity and alcohol will contribute further to a marked increase in liver disease including hepatocellular carcinoma (HCC) which now accounts for 3.5% of all deaths worldwide (3). The absolute burden of viral hepatitis has also increased, although the availability of effective vaccines and treatments may reduce the burden of these diseases in the years to come.

In terms of morbidity, cirrhosis is now the 7th leading cause of disability associated life years (DALY) in people aged 50-74 years and the 12th cause in the 25-49 age range (4), with annual in-hospital costs for cirrhosis in the U.S. alone accounting for over $10 billion (5). Thus, there is an urgent need to try to identify patients with chronic liver diseases (CLD) at an earlier stage and intervene effectively before they progress to cirrhosis and decompensation and/or HCC.

This review article discusses the rationale and available evidence for screening for liver fibrosis in the population.

**Rationale for screening for liver fibrosis**

In order to justify the application of a screening policy by health authorities, the 10 criteria of Wilson and Jungner are often still seen as guiding principles (table 1). CLD with a long asymptomatic phase before cirrhosis develops, is characterized by a relatively well-defined natural
history and a high death rate, meeting the first three criteria (6). Most patients at risk of CLD, however, are seen in primary care where optimal diagnostic strategies are undefined.

In population screening, the sensitivity and specificity of the test used is paramount for minimizing the risk of false negative and false positive cases, respectively. Conventional liver tests, such as serum aminotransferases, have poor sensitivity and specificity for identifying cirrhosis, and a liver biopsy is too invasive for a screening test. Non-invasive tests of fibrosis, such as transient elastography (TE) or serum biomarkers, are widely available and well validated for this purpose, with good acceptability (7). However, longitudinal data using these tests for screening are scarce. Finally, screening using non-invasive tests may be cost-effective but requires validation (8).

Early diagnosis of CLD enables initiation of specific measures or treatments to prevent disease progression and improve survival, including antiviral therapy for HBV or HCV, alcohol abstinence in ALD and behavioral changes and treatment of diabetes and obesity in NAFLD. In addition, patients with cirrhosis, once diagnosed, require surveillance for varices and HCC.

**Non-invasive tools for population screening**

A key challenge is that a test’s performance varies with prevalence of the disease. This is the “spectrum effect”, meaning that in low prevalence populations the sensitivity and the positive predictive value are lower. Further, any test, depending on the nature of the test and the chosen cut-off, is associated with false positive and false negative test results, an inherited limitation of binary decision making. A step-wise algorithm of combining noninvasive tests could reduce the rate of false positive tests (9). In addition, it is important to recognize the limitation of liver biopsy as reference standard and the potential variability of all blood based biomarkers (10) which can challenge the potential as screening tool.

Hagström et al. found only modest prognostic performance (AUROC from 0.54-0.71) of five indirect markers of fibrosis (APRI, FIB-4, BARD, Forns and NFS) to predict future development of cirrhosis and severe liver disease in the general population (11). More successful approaches involve TE, which has been applied as screening tool in >6,000 people from population studies from France, China, Spain and the UK (12-15). TE was in general acceptable, and after availability of the XL probe, which was designed to obtain accurate values for obese subjects, reliable results were obtained in >97% of participants. However, the true diagnostic accuracy with liver biopsy as gold standard is less investigated in the screening setting. In a subgroup analysis of
a biopsy-controlled study, TE had a sensitivity of 86% and specificity of 97% in a population where 6% had advanced fibrosis (15). Some of the tools that could be used in population screening are shown in table 2. Enhanced liver fibrosis test (ELF) has also been proposed, but studies with information about its potential as screening tool of fibrosis are limited (16,17).

**Prevalence of liver fibrosis in general population in different parts of the world**

**Europe**

A limited number of studies have reported results on liver fibrosis screening using different non-invasive methods and cutoffs (table 3) (11,12,14,18-24). Liver fibrosis detection rates ranged between 0.7% and 7.5% in populations-based cohorts vs 18-27% in cohorts at risk for CLD (25). Prevalence of cirrhosis reported in half of the studies ranged from 0.25 to 0.76%. NAFLD was the main cause of liver fibrosis in all studies.

**North America**

Between 1988 and 2016, NAFLD prevalence increased from 20.0% to 31.9%, while that of chronic hepatitis C decreased nearly twofold: 1.6% to 0.9% and chronic hepatitis B and ALD remained stable: 0.3%–0.4% and 0.8%–1.0%, respectively (26).

In NAFLD, prevalence estimates of advanced fibrosis have ranged between 3.2% and 10.3%, depending on the assessment method and population (27,28).

**Asia**

Despite the success of universal infant vaccination and antiviral therapy, chronic hepatitis B affects 0.6-9.8% of the general population and remains a leading cause of cirrhosis and HCC. NAFLD now affects 29.6% of the general population (29). Alcohol consumption is also on the rise.

Few studies have determined the prevalence of liver fibrosis, both in general population and at risk populations (supplementary table 1). Studies from Hong Kong reported increased TE values suggestive of advanced fibrosis in 2% and 17.7% of these two populations, respectively (13,30).

**Other parts of the world**

A Markov simulation based on obesity data in Australia projects a 25% increase in NAFLD by 2030, with 85% increase in cirrhosis and NAFLD-related liver deaths (31). Most cirrhosis deaths
in Latin America are due to alcohol, except for tropical Latin America where the major cause of cirrhosis is hepatitis C. No data on population screening for liver fibrosis are available from Latin America or Africa. In Africa, the major causes of death due to cirrhosis are hepatitis B and hepatitis C (2).

**Potential strategies for screening and Limitations**

A major reason for the low proportion of patients with early diagnosis of advanced fibrosis and/or cirrhosis is the lack of referral pathways, even if elevated liver enzymes are identified in primary care. In addition, the care pathways for ALD or NAFLD are not always well structured. In general, strategies for early diagnosis of CLD, advanced fibrosis and/or cirrhosis can be designed as population-based or targeted screening. A population-based, cross-sectional study with 3,076 participants in the Barcelona area using TE for "at front" screening in primary care reported that TE values <9.2 kPa had highest accuracy to exclude fibrosis stages F2 - F4 (14). A more targeted approach focusing on patients with risk factors, such as harmful alcohol consumption or type-2 diabetes, may result in a higher rates of cirrhosis detected than a global approach (25). The Nottingham liver disease stratification pathway for the identification of advanced CLD (32) used (i) raised AST/ALT ratio ≥ 0.8, (ii) harmful alcohol use or iii) fatty liver index (FLI) ≥ 60 as criteria for referral from primary to secondary care. Among patients fulfilling these criteria, 23% of 968 patients had TE values ≥8 kPa, of whom 39% would have gone undetected. Markov modeling estimated the pathway to be cost-effective (33). Similar one-step pathways but based on APRI score in primary care with subsequent TE, are being evaluated in the population-based screening program for asymptomatic cirrhosis (SEAL) in Germany (https://www.lebervorsorge.de/seal/). To assess two-step screening algorithms, a primary care referral pathway combining FIB-4 and ELF for patients with NAFLD was evaluated in a longitudinal study in London (18). Five times more cases of advanced fibrosis and cirrhosis were detected and unnecessary referrals from primary to secondary care decreased by almost 90% using this strategy.

The implementation of a screening program has to take into account not only region-specific health risk profiles (age, sex, comorbidities, ethnicity) but region-specific participation barriers and health inequities (socio-economic differences, distance and mobility), the structure of the health care system (in particular community and primary care, links to other screening programs
such as colon and breast cancer) as well as regulatory requirements (ethics, data protection, coverage of costs).

A general strategic framework for early diagnosis of CLD based on current knowledge is proposed in figure 1.

**Cost-effectiveness of liver fibrosis screening**

In recent years, evidence regarding the cost-effectiveness of liver fibrosis screening has been mounting. Using non-invasive procedures for risk stratification, and compared to the current standard of care pathways, various economic models show highly cost-effective results. These results are consistent across a wide range of target populations and healthcare systems, mostly in European settings. (8,33-37) Estimates range between $6,000 per quality-adjusted life-year (QALY) in low-prevalence general population settings to $2,000 per QALY in at-risk populations, such as heavy alcohol consumers or patients with metabolic syndrome. These numbers are well below the thresholds that allow new therapies to enter the portfolio of covered services in most developed countries, $100,000 in the US and between $25,000 and $50,000 in Europe. Their importance lies in their opportunity cost. Provided that less cost-effective therapies are being administered, using the same budget but shifting it towards liver fibrosis screening would yield a better societal return.

**Screening in pediatric populations**

Approximately 9.6% of children and adolescents have fatty liver; and 1-2% of the general pediatric population have at least some histopathological evidence of portal and/or perisinusoidal fibrosis associated with fatty liver based on autopsy studies (38), which is lower than the liver fibrosis prevalence in adults. In light of this low prevalence in children, universal screening for liver fibrosis in that population cannot be recommended at this time, but screening should be guided by risk factors, such as personal and family history of liver disease or presence of obesity. Screening for liver fibrosis with serum ALT levels is insufficient in children, as fibrosis can be detected on liver biopsy in 12% of children with suspected NAFLD and normal ALT levels (39). The gold standard in the assessment of pediatric liver fibrosis is still liver biopsy (39), but it might soon be replaced by noninvasive serum and imaging screening modalities, which are getting better at diagnosing (early) liver fibrosis in children (supplementary table 2) (40,41).

**Conclusions and future directions**
There is an urgent need to change the paradigm of diagnosis of CLD from late diagnosis (i.e. decompensated cirrhosis) to early diagnosis (i.e. fibrosis or compensated cirrhosis). This new approach would require identification of asymptomatic patients using non-invasive methods of assessment of fibrosis in large portions of the population. A main lesson learned from cancer screening is that selection of individuals with a high pre-test probability leads to higher economic efficiency. Early research points towards 3-fold improvements in efficiency when at-risk populations are targeted (8). However, there is need for studies with large sample sizes addressing the most important gaps of knowledge, particularly comparing existing non-invasive tests of fibrosis in terms of accuracy and applicability in specific settings, evaluating cost-effectiveness of screening, and investigating potential beneficial effects in the long-term.

There are several initiatives worldwide evaluating the implementation of different methods of screening for liver fibrosis in the population (table 4). When implemented, screening will likely have a remarkable impact on the practice of hepatology. Most patients with CLD may subsequently be detected in early stages, thus potentially decreasing the incidence of hepatic decompensation and HCC and the need for some specialized therapies, such as liver transplantation.
REFERENCES


15: Harman, DJ.; Ryder, SD.; James, MW.; et al. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. Aliment Pharmacol Ther 2018; 47:504-15.


25: Harris, R.; Harman, DJ.; Card, TR.; Aithal, GP.; Guha, IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol 2017; 2:288-297.


30: Kwok, R.; Choi, KC.; Wong, GL.; Zhang, Y.; Chan, HL.; Luk, AO.; et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016; 65:1359-68.

39: Molleston, JP.; Schwimmer, JB.; Yates, KP.; Murray, KF.; Cummings, OW.; Lavine, JE.; et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164: 707-13.
Figure 1. Proposal of a general strategic framework for screening of liver fibrosis in primary care. Current evidence suggests that the target population for screening should have risk factors for chronic liver diseases, including high-risk alcohol consumption and/or components of the metabolic syndrome; the prevalence of liver fibrosis is very low in subjects without these risk-factors (risk stratification I). The first additional step needed is based on a serum surrogate marker of fibrosis with high negative predictive value to rule-out subjects with very low likelihood of fibrosis (risk stratification II). Some screening studies suggest that FIB-4 could be used as marker to rule-out fibrosis, but further studies are necessary (7,25). A single large study suggests that FLI could also be useful, but more information is clearly needed (13). The second step avails of a non-invasive marker of fibrosis to rule-in subjects with high likelihood of significant fibrosis who then should be referred to secondary care or a liver center for further evaluation (screening test in high-risk individuals). Tools/tests to be used in this second step include TE, but this strategy may be expensive and not usually available in primary care settings (7,8,25). ELF has been shown to be accurate in cohorts with high prevalence of fibrosis, but studies are needed in screening populations that have low prevalence of fibrosis (16,25).

* Tests that may be used to rule out hepatic fibrosis include FIB-4 and FLI (fatty liver index)
** Tests that may be used to rule in hepatic fibrosis include TE (transient elastography) and ELF.

ELF, enhanced liver fibrosis test; FIB-4, fibrosis-4 score; FLI, fatty liver index; TE, transient elastography.
Table 1. Summary of the 10 criteria proposed for screening for a disease in the general population *

<table>
<thead>
<tr>
<th>Factors</th>
<th>Criteria</th>
<th>Comment regarding screening for liver diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease</strong></td>
<td>1. The condition sought should be an important health problem</td>
<td>Criterion met</td>
</tr>
<tr>
<td></td>
<td>2. There should be a recognizable latent or early symptomatic stage</td>
<td>Criterion met</td>
</tr>
<tr>
<td></td>
<td>3. The natural history of the condition, including development from latent to declared disease, should be adequately understood</td>
<td>Criterion met</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>4. Facilities for diagnosis and treatment should be available</td>
<td>Further research needed.</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>5. There should be a suitable test or examination</td>
<td>Criterion met</td>
</tr>
<tr>
<td></td>
<td>6. The test should be acceptable to the population</td>
<td>Criterion met</td>
</tr>
<tr>
<td></td>
<td>7. Case-finding should be a continuing process and not a “once and for all” project</td>
<td>Further research needed.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>8. There should be an accepted treatment for patients with recognized disease</td>
<td>Criterion met</td>
</tr>
<tr>
<td></td>
<td>9. There should be an agreed policy on whom to treat the patients</td>
<td>Criterion met**</td>
</tr>
<tr>
<td><strong>Cost-effectiveness</strong></td>
<td>10. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole</td>
<td>Further research needed.</td>
</tr>
</tbody>
</table>

*Adapted from Wilson and Jungner for World Health Organization

** does not apply to ALD, NAFLD, or viral hepatitis in low-income countries
Table 2. Advantages and limitations of non-invasive tests of fibrosis used in population screening

<table>
<thead>
<tr>
<th>Evidence to support</th>
<th>Practical issues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Accuracy in low prevalent populations</td>
</tr>
<tr>
<td>Transient elastography</td>
<td>++</td>
</tr>
<tr>
<td>Direct fibrosis markers e.g. ELF test</td>
<td>+</td>
</tr>
<tr>
<td>Indirect markers e.g. FIB-4</td>
<td>+</td>
</tr>
<tr>
<td>Sequential testing, e.g. FIB-4 and ELF</td>
<td>+</td>
</tr>
</tbody>
</table>

The table rate the current evidence base to support different screening tools and the level of practical barriers for implementation. The rating is arbitrary and combines strength and amount of data. -; none or no data, +; limited, ++; moderate, +++; significant.
<table>
<thead>
<tr>
<th>Author, Year, (Reference)</th>
<th>Country</th>
<th>Sample Size</th>
<th>Setting</th>
<th>Non Invasive Fibrosis Test</th>
<th>Definition of Fibrosis</th>
<th>Prevalence of Fibrosis ≥2</th>
<th>Definition of Cirrhosis</th>
<th>Prevalence of Cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poynard 2010 (15)</td>
<td>France</td>
<td>7463</td>
<td>Consecutive subjects &gt;40 yr attending health examination centers</td>
<td>FibroTest</td>
<td>FibroTest ≥0.48 &amp; LSM ≥ 7.1kPa</td>
<td>0.7-2.8%</td>
<td>FibroTest ≥0.48, LSM ≥ 7.1kPa &amp; clinical sings or liver biopsy</td>
<td>0.1-0.3%</td>
</tr>
<tr>
<td>Roulot 2011 (10)</td>
<td>France</td>
<td>1358 (1190 with valid results)</td>
<td>Consecutive subjects &gt;45 yr attending a medical check-up</td>
<td>TE</td>
<td>LSM ≥ 8 kPa</td>
<td>7.5%</td>
<td>LSM ≥ 13 kPa &amp; Liver Biopsy</td>
<td>0.76%</td>
</tr>
<tr>
<td>Zelber-Sagi 2012 (16)</td>
<td>Israel</td>
<td>375 (338 with valid results)</td>
<td>National Health Survey</td>
<td>FibroTest</td>
<td>FibroTest ≥0.22; FibroTest ≥0.32; FibroTest ≥0.59</td>
<td>25.7%; 12.8%; 0.9%</td>
<td>FibroTest ≥0.75</td>
<td>0.3%</td>
</tr>
<tr>
<td>Koehler</td>
<td>Netherland</td>
<td>3439 (3180 with valid)</td>
<td>Population-based, TE</td>
<td>LSM ≥ 8 kPa</td>
<td>5.6%</td>
<td>LSM ≥ 13 kPa</td>
<td>0.6%</td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>Country</td>
<td>Population</td>
<td>Methodology</td>
<td>TE</td>
<td>LSM (kPa)</td>
<td>Prevalence</td>
<td>Other Notes</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
<td>----</td>
<td>-----------</td>
<td>------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>2016 (17)</td>
<td>Spain</td>
<td>295 (292 with valid results)</td>
<td>Population-based, randomly selected (2/3 with metabolic factors)</td>
<td>TE</td>
<td>LSM ≥ 8kPa</td>
<td>4%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2018 (18)</td>
<td>Spain</td>
<td>3076 (3014 with valid results)</td>
<td>Population-based, randomly selected</td>
<td>TE</td>
<td>LSM ≥ 9.0 kPa</td>
<td>3.6%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2018 (19)</td>
<td>Italy</td>
<td>890</td>
<td>Population-based study</td>
<td>TE</td>
<td>LSM ≥ 9.6 kPa</td>
<td>4%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2018 (12)</td>
<td>Spain</td>
<td>4021 (3600 with valid results, mean age 24)</td>
<td>Avon Longitudinal Study of Parents and Children</td>
<td>TE</td>
<td>LSM ≥ 7.9 kPa</td>
<td>2.4%</td>
<td>LSM ≥ 11.7 kPa 0.25%</td>
<td></td>
</tr>
<tr>
<td>2020 (20)</td>
<td>UK</td>
<td>126,941</td>
<td>Cohort of health check-ups and outpatients from primary care setting</td>
<td>FIB-4, BARD, APRI, Forns, NFS</td>
<td>FIB-4 &gt; 2.67; BARD&gt;3, APRI&gt; 1.5, Forns &gt;6.9, NFS &gt;0.676</td>
<td>0.3-1.4%</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

TE, transient elastography; LSM, liver stiffness measurement

This article is protected by copyright. All rights reserved
Table 4. Examples of projects evaluating screening for liver fibrosis in the population in different areas of the world

<table>
<thead>
<tr>
<th>Name</th>
<th>Geographical area</th>
<th>Area and/or Number of subjects</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>RENOWN</td>
<td>Nevada (USA)</td>
<td>30,000</td>
<td>Subjects with risk factors for NAFLD</td>
</tr>
<tr>
<td>SCARRED LIVER PROJECT</td>
<td>Nottingham (UK)</td>
<td>GP practices in a population of 700,000</td>
<td>Subjects with risk factors for chronic liver disease</td>
</tr>
<tr>
<td>LIVERSCREEN</td>
<td>7 countries in Europe</td>
<td>30,000</td>
<td>Population-based</td>
</tr>
<tr>
<td>SEAL</td>
<td>Germany (2 federal states: Rheinland-Pfalz + Saarland)</td>
<td>12,000 plus 22,500 controls</td>
<td>Detection of asymptomatic cirrhosis in primary care</td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
Figure 1

Subjects with risk factors for chronic liver diseases (CLD)

Step 1
Rule-out

FIB-4 or FLI

FIB-4 ≥ 1.45
or FLI ≥ 60

FIB-4 < 1.45
or FLI < 60

Very low risk of fibrosis
No further assessment

TE or ELF

TE > 9.2 kPa
or ELF ≥ 9.5

Low risk of fibrosis
No further assessment

Refer to secondary care / Liver center

Step 2
Rule-in fibrosis

TE ≤ 9.2 kPa
or ELF < 9.5

This article is protected by copyright. All rights reserved